Martin Perez-Santos

Dr. Martin Perez-Santos

Benemérita Universidad Autónoma de Puebla, Puebla , México
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
Cindy BandalaCindy Bandala
Cindy Bandala
Martin Perez-SantosMartin Perez-Santos
Martin Perez-Santos
ELEleazar Lara-Padilla
Eleazar Lara-Padilla
MLMa. Guadalupe Delgado Lopez
Ma. Guadalupe Delgado Lopez
MAMaricruz Anaya-Ruiz
Maricruz Anaya-Ruiz
The present study was performed to assess the activity of the botulinum toxin A on breast cancer cells. The T47D cell line was exposed to diverse concentrations of the botulinum toxin A and cell viability and apoptosis were estimated using MTT and propidium iodine/annexin V methods, respectively. Botulinum toxin A exerted greater cytotoxic activity in T47D cells in comparison with MCF10A normal cells; this appeared to be via apoptotic processes caspase-3 and -7. In conclusion, botulinum toxin A induces caspase-3 and -7 dependent apoptotic processes in the T47D breast cancer cell line.

1 July 2003 in International Journal for Parasitology
Verified
Journal Article
Closed access
MAM. Anaya-Ruiz
M. Anaya-Ruiz
Martin Perez-SantosMartin Perez-Santos
Martin Perez-Santos
Patricia Talamás-RohanaPatricia Talamás-Rohana
Patricia Talamás-Rohana

5 October 2017 in Genes
Verified
Journal Article
Open access
PDF file
NMNancy Martínez-Montiel
Nancy Martínez-Montiel
MAMaricruz Anaya-Ruiz
Maricruz Anaya-Ruiz
Martin Perez-SantosMartin Perez-Santos
Martin Perez-Santos
RMRebeca Martinez-Contreras
Rebeca Martinez-Contreras
Alternative splicing is a key molecular mechanism now considered as a hallmark of cancer that has been associated with the expression of distinct isoforms during the onset and progression of the disease. The leading cause of cancer-related deaths in women worldwide is breast cancer, and even when the role of alternative splicing in this type of cancer has been established, the function of this mechanism in breast cancer biology is not completely decoded. In order to gain a comprehensive view of the role of alternative splicing in breast cancer biology and development, we summarize here recent findings regarding alternative splicing events that have been well documented for breast cancer evolution, considering its prognostic and therapeutic value. Moreover, we analyze how the response to endocrine and chemical therapies could be affected due to alternative splicing and differential expression of variant isoforms. With all this knowledge, it becomes clear that targeting alternative splicing represents an innovative approach for breast cancer therapeutics and the information derived from current studies could guide clinical decisions with a direct impact in the clinical advances for breast cancer patients nowadays.

30 June 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MAMaricruz Anaya-Ruiz
Maricruz Anaya-Ruiz
Cindy BandalaCindy Bandala
Cindy Bandala
Martin Perez-SantosMartin Perez-Santos
Martin Perez-Santos
MiR-485 Acts as a Tumor Suppressor by Inhibiting Cell Growth and Migration in Breast Carcinoma T47D Cells Breast cancer;microRNA;migration;tumor suppressor; MicroRNAs (miRNAs) are small, non-coding RNAs (18-25 nucleotides) that post-transcriptionally modulate gene expression by negatively regulating the stability or translational efficiency of their target mRNAs. In this context, the present study aimed to evaluate the in vitro effects of miR-485 mimics in breast carcinoma T47D cells. Forty-eight hours after T47D cells were transfected with miR-485 mimics, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was utilized to determine the effects on cell viability. Colony formation and cell migration assays were adopted to determine whether miR-485 affects the proliferation rates and cell migration of breast carcinoma T47D cells. Our results showed that ectopic expression of miR-485 resulted in a significant decrease in cell growth, cell colony formation, and cell migration. These findings suggest that miR-485 might play an important role in breast cancer by suppressing cell proliferation and migration.

30 May 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MAMaricruz Anaya-Ruiz
Maricruz Anaya-Ruiz
JCJorge Cebada
Jorge Cebada
GDGuadalupe Delgado-Lopez
Guadalupe Delgado-Lopez
MSMaria Luisa Sanchez-Vazquez
Maria Luisa Sanchez-Vazquez
Martin Perez-SantosMartin Perez-Santos
Martin Perez-Santos
MiR-153 Silencing Induces Apoptosis in the MDA-MB-231 Breast Cancer Cell Line Breast cancer;microRNA;apoptosis;triple negative;miR-153 silencing; MicroRNAs (miRNAs) are small, non-coding RNAs (18-25 nucleotides) that post-transcriptionally modulate gene expression by negatively regulating the stability or translational efficiency of their target mRNAs. In this context, the present study aimed to evaluate the in vitro effects of miR-153 inhibition in the breast carcinoma cell line MDA-MB-231. Forty-eight hours after MDA-MB-231 cells were transfected with the miR-153 inhibitor, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was utilized to determine the effects of miR-153 on cell viability. Flow cytometry analysis and assessment of caspase 3/7 activity were adopted to determine whether miR-153 affects the proliferation rates and apoptosis levels of MDA-MB-231 cells. Our results showed that silencing of miR-153 significantly inhibited growth when compared to controls at 48 hours, reducing proliferation by 37.6%, and inducing apoptosis. Further studies are necessary to corroborate our findings and examine the potential use of this microRNA in future diagnostic and therapeutic interventions.

4 July 2019 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
IHIrma Herrera-Camacho
Irma Herrera-Camacho
MAMaricruz Anaya-Ruiz
Maricruz Anaya-Ruiz
Martin Perez-SantosMartin Perez-Santos
Martin Perez-Santos
LPLourdes Millán-Pérez Peña
Lourdes Millán-Pérez Peña
Cindy BandalaCindy Bandala
Cindy Bandala
GLGerardo Landeta
Gerardo Landeta
Introduction: TIM3 and PD-1 are checkpoint inhibitors in cancer that coordinate the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of TIM3 and PD-1, and consequently improving the immune response in the various types of cancer. Authors of patent EP3356411A1 propose several anti-TIM3/anti-PD-1 bispecific antibodies, as well as the method for producing them and their pharmacological application in the treatment of cancer. Areas covered: Patent EP3356411A1 describes a method by producing anti-TIM3/anti-PD-1 bispecific antibodies, and their potential in cancer treatment. Expert opinion: Data supporting the patent demonstrate the ability by producing anti-TIM3/anti-PD-1 bispecific antibodies. Although the proposed methodology is very interesting and promising, further studies are necessary to assess the clinical applicability of the inventions on cancer.